Agilent Technologies (NYSE:A) Issues FY 2026 Earnings Guidance

Agilent Technologies (NYSE:A) updated its FY 2026 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 5.900-6.040 for the period, compared to the consensus estimate of 5.930. The company issued revenue guidance of $7.3 billion-$7.5 billion, compared to the consensus revenue estimate of $7.3 billion. Agilent Technologies also updated its Q2 2026 guidance to 1.390-1.420 EPS.

Wall Street Analyst Weigh In

A has been the subject of several research reports. Barclays upgraded Agilent Technologies from an “equal weight” rating to an “overweight” rating and set a $165.00 target price for the company in a research report on Monday, December 15th. Citigroup upped their price target on shares of Agilent Technologies from $165.00 to $185.00 and gave the company a “buy” rating in a report on Tuesday, November 25th. Weiss Ratings restated a “hold (c+)” rating on shares of Agilent Technologies in a research report on Monday, December 29th. The Goldman Sachs Group started coverage on Agilent Technologies in a research report on Tuesday, December 9th. They set a “buy” rating and a $170.00 price objective for the company. Finally, JPMorgan Chase & Co. raised their price objective on Agilent Technologies from $165.00 to $180.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 25th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $164.50.

Agilent Technologies Stock Up 0.4%

Shares of A stock traded up $0.45 on Wednesday, hitting $124.85. The company’s stock had a trading volume of 2,457,707 shares, compared to its average volume of 2,096,712. The stock has a market capitalization of $35.31 billion, a price-to-earnings ratio of 27.32, a P/E/G ratio of 3.61 and a beta of 1.30. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.96 and a quick ratio of 1.52. The firm’s fifty day moving average price is $135.55 and its 200-day moving average price is $136.05. Agilent Technologies has a fifty-two week low of $96.43 and a fifty-two week high of $160.27.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, February 25th. The medical research company reported $1.36 EPS for the quarter, missing analysts’ consensus estimates of $1.37 by ($0.01). The firm had revenue of $1.80 billion during the quarter, compared to the consensus estimate of $1.81 billion. Agilent Technologies had a net margin of 18.75% and a return on equity of 25.20%. Agilent Technologies has set its FY 2026 guidance at 5.900-6.040 EPS and its Q2 2026 guidance at 1.390-1.420 EPS. Research analysts anticipate that Agilent Technologies will post 5.58 EPS for the current year.

Agilent Technologies Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 22nd. Shareholders of record on Tuesday, March 31st will be paid a dividend of $0.255 per share. The ex-dividend date is Tuesday, March 31st. This represents a $1.02 dividend on an annualized basis and a yield of 0.8%. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.32%.

Institutional Trading of Agilent Technologies

Several hedge funds have recently modified their holdings of A. State Street Corp lifted its position in Agilent Technologies by 1.9% during the 4th quarter. State Street Corp now owns 12,681,792 shares of the medical research company’s stock valued at $1,725,611,000 after purchasing an additional 241,029 shares during the period. Morgan Stanley raised its holdings in shares of Agilent Technologies by 15.9% in the fourth quarter. Morgan Stanley now owns 5,041,881 shares of the medical research company’s stock valued at $686,049,000 after purchasing an additional 692,202 shares during the last quarter. Invesco Ltd. lifted its position in Agilent Technologies by 32.0% during the 4th quarter. Invesco Ltd. now owns 2,590,715 shares of the medical research company’s stock worth $352,519,000 after buying an additional 627,804 shares in the last quarter. Ameriprise Financial Inc. boosted its position in Agilent Technologies by 132.2% during the second quarter. Ameriprise Financial Inc. now owns 2,354,111 shares of the medical research company’s stock valued at $277,807,000 after purchasing an additional 1,340,161 shares during the last quarter. Finally, AQR Capital Management LLC grew its stake in shares of Agilent Technologies by 424.1% in the second quarter. AQR Capital Management LLC now owns 2,041,826 shares of the medical research company’s stock valued at $240,956,000 after buying an additional 1,652,244 shares in the last quarter.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.